自2015年起，我們一直跟順勢療法研究院(Homeopathy ResearchInstitute, HRI) (https://www.hri-research.org/resources/homeopathy-faqs/)合作。

除了緊貼世界最新的順勢療法科研之外，總裁杜家麟院士帶領專業團隊與香港中文大學合作，於2012至2016年間進行順勢療法處理糖尿病的隊列研究，並已通過同行評審及出版。

To,K. L. A., Fok, Y. Y. Y., Chong, K. C. M., Lee, Y. C. J., & Yiu, L. S. S.(2017).Individualized homeopathic treatment in addition to conventional treatment intype II diabetic patients in Hong Kong–a retrospective cohort study.Homeopathy,106(02), 79-86.

2017年杜家麟院士亦已開始跟順勢療法研究院系統綜述團隊合作，進行為期三年的一系列系統性綜述(Systematic Review)，陸續經同行評審及出版。Mathie, R. T., Fok, Y. Y., Viksveen, P., To, A. K., & Davidson, J. R. (2019). Systematicreview and meta-analysis of randomised, other-than-placebo controlled, trials ofnon-individualised homeopathic treatment.Homeopathy, 108(02), 088-101.

2019年，全球新冠肺炎(Covid)大流行，杜家麟院士就活躍於相關的科學研究項目，首先是出版了全球第一個COVID-19的順勢療法個案系列，更獲世界衛生組織資料庫收錄：To, K. L. A., & Fok, Y. Y. Y. (2020). Homeopathic clinical features of 18 patients inCOVID-19 outbreaks in Hong Kong.Homeopathy, 109(03), 146-162.（註3）註3：WHO已於2024年1月，將「全球新冠文獻資料庫」封存。

之後，在本地的第一波爆發及OMICRON爆發時，為順勢療法專業作出貢獻，令全球同行均可受益，並肩在此前所未見的疫症中砥礪前行。

Tournier, A., Fok, Y., van Haselen, R., & To, A. (2023). Homeopathic Treatment ofCOVID-19 Patients: Findings of the Clificol International Clinical Case Registry.Integrative Medicine Reports, 2(1), 87-96.

Tournier, A., Fok, Y., van Haselen, R., & To, A. (2024). The SymptomaticExpression in Chinese Patients with Suspected COVID-19 Omicron VariantInfection: A Clinical Case Registry Study. OBM Integrative and ComplementaryMedicine, 9(3), 1-26.

•  科研出版：中國疑似COVID-19 Omicron變異感染患者的症狀表現：臨床病例登記研究
• Tournier, A., Fok, Y., van Haselen, R., & To, A. (2024). The SymptomaticExpression in Chinese Patients with Suspected COVID-19 Omicron VariantInfection: A Clinical Case Registry Study. OBM Integrative and ComplementaryMedicine, 9(3), 1-26.

• 10/04科研出版：COVID-19患者的順勢療法治療：Clificol國際臨床病例註冊的結果。Tournier, A., Fok, Y., van Haselen, R., & To, A. (2023). Homeopathic Treatment ofCOVID-19 Patients: Findings of the Clificol International Clinical Case Registry.Integrative Medicine Reports, 2(1), 87-96.

2022/

• 10/02科研出版：尋找中國患者的流行特效療劑：來自ClificolCOVID-19臨床病例記錄庫的發現Tournier, A., Fok, Y., van Haselen, R., &To, A. (2023). Searching for the genus epidemicus in Chinese patients:findings from the Clificol COVID-19 Clinical Case Registry.Homeopathy,112(01), 030-039.

2021/

• 04/06科研出版：來自中國的更新：大規模疫情中順勢療法的臨床和研究To, K. L. A., & Fok, Y. Y. Y. (2021). Updates from China: clinical and researchexperience of homeopathy in the pandemic. International Journal of HighDilution Resarch, 20(1).

2020/

• 06/05科研出版：香港COVID-19疫情中18例患者的順勢療法臨床特徵

• To, K. L. A., & Fok, Y. Y. Y. (2020). Homeopathic clinical features of 18 patients inCOVID-19 outbreaks in Hong Kong.Homeopathy,109(03), 146-162.

• 01/30科研出版：隨機順勢療法非個人化、非安慰劑對照試驗的系統評價及薈萃分析Mathie, R. T., Fok, Y. Y., Viksveen, P., To, A. K., & Davidson, J. R. (2019). Systematicreview and meta-analysis of randomised, other-than-placebo controlled, trials ofnon-individualised homeopathic treatment.Homeopathy,108(02), 088-101.

• 03/17科研出版：在香港於二型糖尿病人的常規治療上加入個人化順勢療法處理——回顧性隊列研究To, K. L. A., Fok, Y. Y. Y., Chong, K. C.M., Lee, Y. C. J., & Yiu, L. S. S. (2017). Individualized homeopathictreatment in addition to conventional treatment in type II diabetic patientsin HongKong–a retrospective cohort study.Homeopathy,106(02),79-86.